PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells

Oncology Reports

Volumn 21, Issue 3, 2009, Pages 731-735

  Bouali, Sanae ^a,b   Chrétien, Anne Sophie ^a,b   Ramacci, Carole ^a,b   Rouyer, Marie ^a,b   Becuwe, Philippe ^b   Merlin, Jean Louis ^a,b  

^a CENTRE ALEXIS VAUTRIN   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Cetuximab; Epidermal growth factor receptor; Gene transfer; KRAS; PTEN

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; S6 KINASE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER HORMONE THERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG MECHANISM; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MALE; NULL CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WILD TYPE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RAF KINASES; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 64849093363     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000278     Document Type: Article

References (22)

1. Mendelsohn J and Baselga J: The EGF receptor family as targets for cancer therapy. Oncogene 19: 6550-6565, 2000.
2. Yarden Y: The EGFR family and its ligands in human cancer: signaling mechanisms and therapeutic opportunities. Eur J Cancer 37 (Suppl 4): S3-S8, 2001.
3. Lièvre A, Bachet JB, Le Corre D, et al: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995, 2006.
4. Lièvre A, Bachet JB, Boige V, et al: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26: 374-379, 2008.
5. Merlin JL, Perkins G, Lièvre A, et al: Additional value of EGFR downstream signaling phosphoprotein expression to KRas mutation for response prediction to cetuximab in colorectal cancer. J Clin Oncol 26: S209, 2008.
6. Cho NY, Choi M, Kim BH, Cho YM, Moon KC and Kang GH: BRAF and KRAS mutations in prostatic adenocarcinoma. Int J Cancer 119: 1858-1862, 2006.
7. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M and Sellers WR: Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Clin Cancer Res 59: 4291-4296, 1999.
8. Maehama T and Dixon JE: The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphati-dylinositol 3,4,5-trisphosphate. J Biol Chem 273: 13375-13378, 1998.
9. Sakata K, Kato S, Fox JC, Shigemori M and Morimatsu M: Autocrine signaling through Ras regulates cell survival activity in human glioma cells: potential cross-talk between Ras and the phosphatidylinositol 3-kinase-Akt pathway. J Neuropathol Exp Neurol 61: 975-983, 2002.
10. Frattini M, Saletti P, Romagnani E, et al: PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97: 1139-1145, 2007.
11. Schimanski CC, Linnemann U and Berger MR: Sensitive detection of K-Ras mutations augments diagnosis of colorectal cancer metastases in the liver. Cancer Res 59: 5169-5175, 1999.
12. Maurice-Duelli A, Ndoye A, Bouali S, Leroux A and Merlin JL: Enhanced cell growth inhibition following PTEN nonviral gene transfer using polyethylenimine and photochemical internalization in endometrial cancer cells. Technol Cancer Res Treat 3: 459-465, 2004.
13. Chrétien AS, Chergui F, Bastogne T, et al: Validation of phosphoprotein array assay for the determination of human epidermal growth factor receptors downstream signaling phosphoproteins in breast cancer. Eur J Cancer 9: 96, 2008.
14. Sharrard RM and Maitland NJ: Phenotypic effects of overexpression of the MMAC1 gene in prostate epithelial cells. Br J Cancer 83: 1102-1109, 2000.
15. Davies MA, Kim SJ, Parikh NU, et al: Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells. Clin Cancer Res 8: 1904-1914, 2002.
16. Tanaka M, Rosser CJ and Grossman HB: PTEN gene therapy induces growth inhibition and increases efficacy of chemotherapy in prostate cancer. Cancer Detect Prev 29: 170-174, 2005.
17. Li X, Luwor R, Lu Y, Liang K and Fan Z: Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTEN-deficient cancer cells. Oncogene 25: 525-535, 2006.
18. Nagata Y, Lan K-H, Zhou X, et al: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117-127, 2004.
19. Merlin JL, Genin P, Harle A, et al: Phosphoprotein array in tumor biopsies for molecular diagnostis of PI3 kinase and MAP kinase signaling functionality. Mol Cancer Ther 6: S3540, 2007.
20. Merlin JL, Longavenne E, Chergui F, et al: Exploring human epidermal growth factor receptors downstream signaling by multiplex phosphoprotein determination in breast cancer. Proc Am Assoc Cancer Res 47: 3607, 2006.
21. Merlin JL, Mriouah J, Dolivet G, et al: Signaling phospho-proteins in head and neck squamous cell carcinoma: relation with cellular sensitivity to cetuximab and interest of multiplex determination using Bio-Plex protein array. Proc Am Assoc Cancer Res 48: 185, 2007.
22. McRae EJ, Giannoudis A, Ryan R, et al: Gene therapy for prostate cancer: current strategies and new cell-based approaches. Prostate 66: 470-494, 2006.